Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study

OBJECTIVE: To evaluate the impact of two calcitonin gene–related peptide (CGRP)‐targeted monoclonal antibodies (mAbs), erenumab and galcanezumab, on the pharmacokinetic (PK) profile, safety, and tolerability of ubrogepant. BACKGROUND: People taking CGRP‐targeted mAbs for migraine prevention sometime...

Full description

Saved in:
Bibliographic Details
Published in:Headache
Main Authors: Jakate, Abhijeet, Blumenfeld, Andrew M., Boinpally, Ramesh, Butler, Matthew, Borbridge, Lisa, Contreras‐De Lama, Janette, McGeeney, Danielle, Periclou, Antonia, Lipton, Richard B.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2021
Subjects:
Research Submissions
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8252052/
https://ncbi.nlm.nih.gov/pubmed/33818780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.14095
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items